TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07453602: Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Sponsor: Arcutis Biotherapeutics, Inc. · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 125 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$210,528

Rescue Site Savings

+$140,352

Unlock Full NCT07453602 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07453602 Rescue Dossier →